Kolobukhina L V, Merkulova L N, Shchelkanov M Iu, Burtseva E I, Lavrishcheva V V, Samokhvalov E I, Al'khovskiĭ S V, Prilipov A G, Proshina E S, Avdeev S N, Sutochnikova O A, Bazarova M V, Kelli E I, Tserukalova N D, Blank I A, Shestakova O M, Kolivashko O N, Arseneva T V, Ambrosi O E, Shul'diakov A A, Popov A F, Simakova A I, Malyshev N A, Chuchalin A G, L'vov D K
Ter Arkh. 2011;83(9):48-53.
To assess efficacy and safety of ingavirin in the treatment of the flu caused by pandemic virus of flu A (H1N1) sw1 in hospitalized patients compared with oseltamivir.
A population-based comparative multicenter trial included 194 patients with verified diagnosis of the flu aged 18-60 years with marked clinical symptoms, body temperature over 38 degrees C and duration of the disease 48 hours maximum. The patients were randomized into 2 groups: group 1 (n=152) received ingavirin (90 mg once a day), group 2 received oseltamivir (n=42) in a dose 150 mg twice a day. Duration of the course was 5 days.
Ingavirin and oseltamivir normalized body temperature within treatment hours 24-36 if therapy was initiated in the first disease hours 27.0 +/- 10.0 and 31.9 +/- 10.4. Mean duration of the fever for ingavirin was 35.1 +/- 14.5 hours, for oseltamivir--26.3 +/- 13.0 hours (p < 0.817). The antiviral medicines significantly reduced duration of intoxication (head ache, weakness), catarrhal symptoms (cough, tracheitis, rhinitis), rate of complication vs. patients untreated with antivirus drugs (n=30).
The results of the treatment show safety and efficacy of ingavirin in uncomplicated flu caused by pandemic virus of flu A (H1N1) sw1 in inpatients. Early etiotropic therapy is a basic treatment policy able to reduce the number of severe complications and lethality.
与奥司他韦相比，评估因加维林治疗甲型流感病毒（H1N1）sw1大流行病毒引起的流感的疗效和安全性。
一项基于人群的比较多中心试验纳入了194例确诊为流感的患者，年龄在18至60岁之间，有明显临床症状，体温超过38摄氏度，病程最长48小时。患者被随机分为2组：第1组（n = 152）接受因加维林（每日一次，90毫克），第2组接受奥司他韦（n = 42），剂量为每日两次，每次150毫克。疗程为5天。
如果在发病的最初27.0 +/- 10.0小时和31.9 +/- 10.4小时开始治疗，因加维林和奥司他韦可在治疗后24 - 36小时内使体温恢复正常。因加维林的平均发热持续时间为35.1 +/- 14.5小时，奥司他韦为26.3 +/- 13.0小时（p < 0.817）。与未接受抗病毒药物治疗的患者（n = 30）相比，这些抗病毒药物显著缩短了中毒（头痛、虚弱）、卡他症状（咳嗽、气管炎、鼻炎）的持续时间以及并发症发生率。
治疗结果表明，因加维林治疗甲型流感病毒（H1N1）sw1大流行病毒引起的非复杂性流感对住院患者具有安全性和有效性。早期病因治疗是能够减少严重并发症数量和死亡率的基本治疗策略。
